Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 15
- Registration Number
- NCT02419378
- Locations
- 🇩🇪
Universitätsklinikum Münster, Klinik für Allgemeine Neurologie, Münster, Germany
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
- Conditions
- Interventions
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02385110
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 57
- Registration Number
- NCT02162420
- Locations
- 🇺🇸
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
- Conditions
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 56
- Registration Number
- NCT02105766
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Diane George
- Target Recruit Count
- 14
- Registration Number
- NCT02061800
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 34
- Registration Number
- NCT02059239
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Damiano Rondelli, MD
- Target Recruit Count
- 2
- Registration Number
- NCT02013375
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Conditions
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 100
- Registration Number
- NCT01962415
- Locations
- 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Stem Cell Transplantation for Sickle Cell Anemia
- Conditions
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 30
- Registration Number
- NCT01877837
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
- Conditions
- Interventions
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01875237
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.